Acadia Healthcare Hits New 52-Week High at $35.64, Signaling Recovery

Acadia Healthcare Co., Inc. has reached a significant milestone by hitting a new 52-week high of USD 35.64 on July 21, 2026. This achievement comes amidst a challenging year for the company, which has seen its stock price decline by 48.83% over the past year, contrasting sharply with the S&P 500's performance of 19.09% during the same period. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Acadia Healthcare has a market capitalization of USD 2,113 million. The company's price-to-earnings (P/E) ratio stands at 10.00, indicating its valuation relative to earnings. Additionally, Acadia's return on equity is reported at 10.39%, reflecting its efficiency in generating profits from shareholders' equity. Despite the recent high, the stock's performance metrics, including a price-to-book ratio of 1.08 and a debt-to-equity ratio of 1.23, provide insight into its financial health. The company currently does not offer a dividend yield, which is noteworthy for investors considering income-generating stocks.